Pfizer begins Chantix push

NEW YORK: Pfizer is talking to patient and advocacy groups to educate them about how to quit smoking and to promote its anti-smoking drug Chantix, which received approval on May 11 from the Food and Drug Administration (FDA).

NEW YORK: Pfizer is talking to patient and advocacy groups to educate them about how to quit smoking and to promote its anti-smoking drug Chantix, which received approval on May 11 from the Food and Drug Administration (FDA).

Edelman, who won the account in February after Chandler Chicco Agency (CCA) was dropped by Pfizer, will handle.

Chantix, previously referred to as Champix, is the brand-name for varenicline, which works neurochemically to dampen the pleasurable stimulae smokers get from lighting up. As the first new anti-smoking drug released in a decade, it received priority review from the FDA because of its potential to have therapeutic advantages over the existing treatments, such as GlaxoSmithKline’s Zyban.

 “We realize there is a major education effort needed to educate people about the addictions of smoking and to show them that nicotine addiction is a serious issue,” says Jean Traflet, director of PR for Pfizer.

She said Pfizer consulted third parties and government agencies who are involved in educating the public about the dangers of smoking.  Edelman had no comment about the effort.

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in